CMS spokesman Aaron Albright and Theranos both confirmed the proposal was submitted, according to the report. Mr. Albright told Bloomberg CMS staff is currently reviewing the proposal.
CMS released a letter in January that summarized the deficient practices found in a November inspection at Theranos’ Newark, Calif., lab, which included five major infractions for a range of issues including hematology practices, analytic systems and personnel issues. Theranos had 10 days to submit a plan of correction, and it filed for an extension earlier this month.
More articles on leadership and management:
Massachusetts General vs. Johns Hopkins: 6 key comparisons
Why the cancer ‘moonshot’ is not a fitting metaphor
What Justice Scalia’s death could mean for healthcare: 7 things to know
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.